Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aspire Biopharma Holdings Inc (ASBP)

Aspire Biopharma Holdings Inc (ASBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) ACCESS Newswire - Wed Jan 7, 2:00AM CST

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine ACCESS Newswire - Thu Dec 18, 2025

A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements ACCESS Newswire - Fri Dec 12, 2025

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, received...

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire Biopharma Provides Q3 2025 Business Update ACCESS Newswire - Thu Dec 4, 2025

ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today...

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) ACCESS Newswire - Tue Dec 2, 2025

ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology,...

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member ACCESS Newswire - Wed Nov 26, 2025

ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, has...

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin ACCESS Newswire - Thu Nov 6, 2025

ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today...

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) ACCESS Newswire - Wed Sep 3, 2025

Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 ACCESS Newswire - Thu Aug 14, 2025

ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology,...

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World ACCESS Newswire - Wed Aug 13, 2025

BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential

ASBPW : 0.0300 (+4.90%)
ASBP : 0.1040 (+0.68%)

Barchart Exclusives

As Meta Delays New Ray-Ban Display Glasses, Should You Buy, Sell, or Hold META Stock? Barchart - Sat Jan 10, 2:19PM CST
Meta’s pause on the global rollout of its Ray-Ban Display smart glasses leaves investors to weigh whether META is a buy, sell, or hold at this pivotal moment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot